Is Sarepta a good buy?
Sarepta Therapeutics has received a consensus rating of Moderate Buy. The company’s average rating score is 2.77, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.
Is Srpt stock a buy?
The 19 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 114.00, with a high estimate of 160.00 and a low estimate of 74.00. The median estimate represents a +66.37% increase from the last price of 68.52.
Is Sarepta a biotech company?
Sarepta is a global biotechnology company on an urgent mission: engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases.
Why did Srpt stock drop?
Sarepta Therapeutics SRPT +4.73% stock is falling after the biotech company said it would sell more stock and provided an update on product revenue. Sarepta said that it would post third-quarter sales of $166.9 million.
What does Sarepta Therapeutics do?
Who We Are. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
Who makes Sarepta?
As of the end of 2019, the company has two approved drugs (see the Products section below). Sarepta Therapeutics, Inc….Sarepta Therapeutics.
| Traded as | Nasdaq: SRPT Russell 1000 Index component |
|---|---|
| Headquarters | Cambridge |
| Key people | Douglas S. Ingram (CEO & President) |
| Revenue | $301 Million(2018) |
| Website | www.sarepta.com |
How many employees does Sarepta have?
Interactive chart of Sarepta Therapeutics (SRPT) annual worldwide employee count from 2010 to 2022. Sarepta Therapeutics total number of employees in 2021 was 840, a 3% decline from 2020. Sarepta Therapeutics total number of employees in 2020 was 866, a 16.55% increase from 2019.
Is Sarepta a good company to work for?
Is Sarepta Therapeutics a good company to work for? Sarepta Therapeutics has an overall rating of 4.1 out of 5, based on over 89 reviews left anonymously by employees. 78% of employees would recommend working at Sarepta Therapeutics to a friend and 79% have a positive outlook for the business.
What is the price of Sarepta Therapeutics stock now?
Since then, SRPT stock has decreased by 30.8% and is now trading at $71.10. View which stocks have been most impacted by COVID-19. When is Sarepta Therapeutics’ next earnings date?
What did Sarepta Therapeutics CEO Douglas Ingram buy?
Douglas S Ingram, CEO at Sarepta Therapeutics (NASDAQ:SRPT), made a large insider buy on November 17, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Ingram purchased 25,026 shares of Sarepta Therapeutics at at a price of $79.94.
What is Sarepta Therapeutics’email address?
Sarepta Therapeutics’ mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (857) 242-4000, via email at [email protected], or via fax at 425-354-5038.
What is Sarepta about?
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases.